EUVIMEDEUVIMED entdecken
Metaanalyse

Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis

Hendrik S Fischer, Nora J Reibel, Christoph Bührer, Christof Dame

Neonatology · 2023 · 120 (5) · 566-576

DOI: 10.1159/000530126 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Neonatology, online erschienen am 27.06.2023. Verfasst von Hendrik S Fischer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Retinopathy of Prematurity, Anemia, Neonatal, Erythropoietin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recombinant human erythropoietin (rhEPO) lost its role in minimizing red blood cell transfusion in very preterm infants after it had been associated with severe retinopathy of prematurity (ROP). Previous systematic reviews did not stratify ROP by gestation and birth weight (BW).

Objectives

The aim of this study was to investigate the effect of early prophylactic rhEPO on ROP in a stratified meta-analysis of randomized controlled trials (RCTs).

Methods

The databases EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials were searched in January 2022 and complemented by citation searching. RCTs comparing early rhEPO treatment with no treatment or placebo were selected if they were published in a peer-reviewed journal and reported ROP outcomes. Previously unpublished data were requested from the study authors to allow stratified analyses by gestational age (GA) and BW. Data were extracted and analyzed using the standard methods of the Cochrane Neonatal Review Group. Pre-specified outcomes were “ROP stage ≥3” (primary outcome) and “any ROP.” Results: Fourteen RCTs, comprising 2,040 infants of <29 weeks of GA, were included for meta-analysis. Data syntheses showed no effects of rhEPO on ROP stage ≥3 or on any ROP, neither in infants of <29 weeks GA, nor in infants of <1,000 g BW, nor in any GA strata. The risk ratio (95% confidence interval) for ROP stage ≥3 in infants of <29 weeks of GA was 1.13 (0.84, 1.53), p = 0.41 (quality of evidence: moderate).

Conclusions

The present meta-analysis detected no effects of early rhEPO on ROP in any comparison, but most stratified analyses were limited by low statistical power.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinopathy of PrematurityAnemia, NeonatalErythropoietinInfant, NewbornHumansInfant, PrematureBirth WeightInfant, Very Low Birth WeightGestational AgeRisk Factors

Stichwörter der Autor:innen

Anemia of prematurityErythropoietinMeta-analysisRetinopathy of prematurity

Substanzen

Erythropoietin

Autor:innen und Institutionen

  • Department of Neonatology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Zitieren

APA

Fischer, H. S., Reibel, N. J., Bührer, C., & Dame, C. (2023). Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis. Neonatology, 120(5), 566-576. https://doi.org/10.1159/000530126

Vancouver

Fischer HS, Reibel NJ, Bührer C, Dame C. Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis. Neonatology. 2023;120(5):566-576. doi:10.1159/000530126

BibTeX
@article{Fischer2023,
  author = {Fischer, Hendrik S and Reibel, Nora J and Bührer, Christoph and Dame, Christof},
  title = {Effect of Early Erythropoietin on Retinopathy of Prematurity: A Stratified Meta-Analysis},
  journal = {Neonatology},
  year = {2023},
  volume = {120},
  number = {5},
  pages = {566--576},
  doi = {10.1159/000530126}
}
Kostenlos starten →